Home Diagnostics, Inc. Wins Governor's Export Excellence Award

Home Diagnostics won the award as a result of its strategic expansion into Latin America and more than 80 percent of the countries in Europe. Data suggests that Home Diagnostics has increased its market share throughout Latin America, as well as in the United Kingdom where it recently launched a new blood glucose monitoring system called TRUEone. Continued international expansion is a key strategic initiative for Home Diagnostics as it plans expansions into Asia and Europe in 2010.

"Our team is honored to be recognized with the Governor's Export Excellence Award. We remain committed to supporting Florida's economy while delivering high-quality diabetes testing supplies to people with diabetes across the globe," said Joe Capper, president and CEO of Home Diagnostics. "Home Diagnostics is proud to help represent the best of the Sunshine State's vibrant economy, technological innovation and job creation."

The Governor's Business Diversification Awards are coordinated by Enterprise Florida Inc., a public-private partnership serving as Florida's primary organization devoted to statewide economic development. Enterprise Florida's mission is to diversify the state's economy and create better-paying jobs for its citizens by supporting, attracting and helping to create businesses in innovative, high-growth industries.

The 2009 Governor's Business Diversification Awards winners were honored at a ceremony on Tuesday, September 15, 2009 in Tallahassee, Florida.

About Home Diagnostics, Inc.

Based in Fort Lauderdale, Florida, Home Diagnostics, Inc. (NASDAQ:HDIX) is a leading developer, manufacturer and marketer of diabetes management products. Home Diagnostics, Inc. offers a portfolio of high-quality blood glucose monitoring systems that spans the spectrum of features and benefits to help every person with diabetes better monitor and manage their disease. The Home Diagnostics, Inc. product line includes TRUE2go(TM), TRUEresult(R), TRUEbalance(TM), TRUEtrack(R), Sidekick(R), TRUEread(R) and Prestige Smart System(R) blood glucose monitoring systems. The products are available in more than 45,000 pharmacies throughout the U.S. Home Diagnostics is the exclusive co-brand supplier of blood glucose monitoring systems for leading pharmacies including CVS, Rite Aid and Walgreens, as well as distributors such as AmerisourceBergen, Cardinal Health, McKesson, Invacare and Liberty Medical. Home Diagnostics, Inc. was named one of Forbes magazine's "200 Best Small Companies" in 2008, and in 2009 received several recognitions for the company's TRUE2go blood glucose meter, including a Medical Design Excellence Award (MDEA) and a Gold Award in the Medical/Test Equipment category as part of appliance DESIGN Magazine's 22nd Annual Excellence in Design (EID) Awards Competition. For more information please visit www.homediagnostics.com.

Forward-Looking Statements

The above statements include forward-looking statements and are subject to risks and uncertainties. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. The statements can be identified by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.

All statements other than statements of historical facts included in this release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements.

These forward-looking statements are largely based on our expectations and beliefs concerning future events, which reflect estimates and assumptions made by the Company's management. These estimates and assumptions reflect the Company's best judgment based on currently known market conditions and other factors relating to the Company's operations and business environment, all of which are difficult to predict and many of which are beyond its control.

Although the Company believes its estimates and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond the Company's control. In addition, management's assumptions about future events may prove to be inaccurate. Management cautions all readers that the forward-looking statements contained in this release are not guarantees of future performance, and the Company cannot assure any reader that those statements will be realized or the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied in the forward-looking statements due to the factors listed in the "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" sections contained in its filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release. The Company does not intend to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise, except as required by law. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.

TRUE2go, TRUEresult, TRUEtrack, TRUEbalance, Sidekick, TRUEread and Prestige Smart System are trademarks of Home Diagnostics, Inc. All other trademarks are property of their respective owners.

[HDIX-F]

SOURCE: Home Diagnostics, Inc.

Home Diagnostics, Fort Lauderdale 
Sabrina Rios, Corporate Communications Manager, 954-332-2141 
srios@hdidiabetes.com 
or 
Schwartz Communications 
Marisa Borgasano or Jennifer Barlow, Media Relations, 781-684-0770 
homediagnostics@schwartz-pr.com